# GEOMETRY-N (NCT04926831)

> Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

No report yet. It can be ordered.

- Drugs tested: capmatinib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04926831
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Non-small Cell Lung Cancer
- Interventions: capmatinib
- Enrollment: 4
- Primary outcome: Major Pathological Response (MPR) Rate

## Indexed commentary on GEOMETRY-N so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=geometry-n-nct04926831